Home / Pharmaceutical / Hepatitis B Vaccine Market By Composition (Combination Vaccines, Mono Vaccines), By End Users Age (Adult Hepatitis B Vaccines, Paediatric Hepatitis B Vaccines) - Growth, Future Prospects And Competitive Analysis 2022 - 2030

Hepatitis B Vaccine Market By Composition (Combination Vaccines, Mono Vaccines), By End Users Age (Adult Hepatitis B Vaccines, Paediatric Hepatitis B Vaccines) - Growth, Future Prospects And Competitive Analysis 2022 - 2030

Factors such as increase in awareness of hepatitis B infection prevention, governments have mandated the immunization and hepatitis B vaccine included in national immunization schedule in many countries driving the market growth of hepatitis B vaccine globally.

The report titled “Hepatitis B Vaccine Market - Growth, Future Prospects and Competitive Analysis, 2022–2030” offers strategic insights into the overall hepatitis B vaccine market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on composition, end users age and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hepatitis B vaccine market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hepatitis B vaccine market. This report concludes with company profiles section that highlights major information about the key players engaged in global hepatitis B vaccine market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.      

Composition analysis:

Hepatitis B is a life threatening liver infection caused by the hepatitis B virus. Vaccine is most effective than any other treatment in preventing infection. According to WHO (world health organization), prevalence of hepatitis B is highest in Western Pacific and African region however, lowest in American population. Factors such as an increase in awareness of vaccines are expected to contribute the market growth of hepatitis B vaccine globally. For the purpose of study market is segmented on the basis of composition of vaccine such as mono and combination vaccine. Combination vaccines that protect against multiple pathogens, it involves combination of multiple antigens into a single vaccine. Combination vaccine such as Infanrix Hexa, Hexaci ma/Hexyon, Twinrix, Ambirix, Comvax widely used for the prevention of hepatitis B infection. It is observed that, combination vaccine is major revenue generating segment. Factors such as higher patient compliance, reduced number of dose frequency, better disease control, coverage of vaccine under national immunization program and reduced chances of missing immunization are driving the growth of combination vaccine market globally. It is observed that mono vaccines such as Recombi vax HB, Fendrix and Engeri x-B are approved for the treatment of hepatitis B infection.

End user age group analysis:

Hepatitis B virus cause life threatening liver disease, vaccine is more effective than any other treatment in preventing infection. The choice of hepatitis B vaccine varies with the age. Adult Hepatitis B Vaccines are used for active immunization of individuals aged above 18 and 21 in Europe and US respectively. Hepatitis B is one of the most common travelers diseases which can be avoided by vaccine immunization. Governments across the world have mandated the immunization of travelers, which is acting as a growth driver for the hepatitis B vaccines market across the world. It is observed that in base 2016, adult hepatitis B vaccines held largest market share as adults have high risk of developing hepatitis B infections due to end-stage renal disease, drug abuse and HIV infection which is driving the market growth of adult hepatitis B vaccines globally. In terms of immunogenicity, pediatric vaccines differ from adult vaccines. Pediatric hepatitis B vaccines are used for the prevention of hepatitis B infection in infants, toddlers, and adolescents because babies and young children are at higher risk for developing the potentially fatal complications of the infection. It is estimated that pediatric hepatitis B vaccines will show steady growth rate during forecast period. It is observed that pediatric vaccines such Infanrix, hexa, Hexacima/Hexyon, Ambirix, and Comvax. Infanrix hexa are widely accepted in market.

Hepatitis B is life threatening liver disease that can cause acute and chronic liver infection and may lead to cirrhosis and liver cancer. Safe and effective vaccines are available in market to prevent hepatitis B infection. According to World Health Organization (WHO) prevalence of hepatitis B is highest in Western Pacific and in African region more than 6% of the adult population is affected with hepatitis B infection. In South East Asia and European region, it is estimated that 2% and 1.6% of the general population is affected with hepatitis B, respectively. The burden of hepatitis B infection is considerably less in the American population which is approximately 0.7% of the overall population. It is observed that in the base year 2021, North America was major revenue contributing segment. Factors such as higher cost of vaccines, immunization programs and favorable R&D activities driving the market growth in North America. Currently, Asia Pacific is not major revenue generating segment but it is estimated that it will show highest CAGR during forecast period. Rising healthcare awareness, populous countries, increase in awareness of vaccines, government initiative in vaccination program would influence the growth of hepatitis B vaccine market in Asia Pacific region.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hepatitis B Vaccine market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Hepatitis B Vaccine market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Research Period  2020-2030
Base Year 2021
Forecast Period  2022-2030
Historical Year  2020
Unit  USD Million
  • Combination Vaccines
  • Mono Vaccines

End Users Age
  • Adult Hepatitis B vaccines
  • Paediatric Hepatitis B vaccines

 Region Segment (2020–2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
  • Pre Covid-19 situation
  • Post Covid-19 situation

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Hepatitis B Vaccine market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Hepatitis B Vaccine market?
  • Which is the largest regional market for Hepatitis B Vaccine market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Hepatitis B Vaccine market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Hepatitis B Vaccine market worldwide?
Choose License Type
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +